Tens of thousands of additional injections were billed to Medicaid and Tricare during those same years, according to federal ...

Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery.

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central ...

Virpax Pharmaceuticals (VRPX) announced the completion of the full study that followed the initial Probudur pilot study performed by the U.S.

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug ...

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...

BERWYN, Pa. - Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX), a micro-cap pharmaceutical company with a market capitalization of $1.43 million focused on non-addictive pain management treatments, has ...

bupivacaine, in both efficacy and duration. “We are very pleased with the results, whi “Channel Therapeutics” reflects the Company’s focus on developing therapeutics to treat pain ...

Providing pain relief during surgical animal husbandry procedures is a better choice for your livestock, your business and ...

BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced the successful completion of a full study on its ...

Uncomplicated skin infections account for almost 200 million physician-office visits in the USA annually. Treating these infections is estimated to cost in excess of US$350 million each year. The ...